[go: up one dir, main page]

WO2018065076A1 - Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles - Google Patents

Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles Download PDF

Info

Publication number
WO2018065076A1
WO2018065076A1 PCT/EP2016/076104 EP2016076104W WO2018065076A1 WO 2018065076 A1 WO2018065076 A1 WO 2018065076A1 EP 2016076104 W EP2016076104 W EP 2016076104W WO 2018065076 A1 WO2018065076 A1 WO 2018065076A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
dysmenorrhea
estetrol
component
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2016/076104
Other languages
English (en)
Inventor
Maud JOST
Glwadys RAUSIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Estetra SRL
Original Assignee
Estetra SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra SRL filed Critical Estetra SRL
Priority to CA3178291A priority Critical patent/CA3178291A1/fr
Priority to MYPI2019002318A priority patent/MY205032A/en
Priority to JP2017529086A priority patent/JP2018533542A/ja
Priority to CA3041016A priority patent/CA3041016C/fr
Priority to KR1020197015235A priority patent/KR102780201B1/ko
Priority to KR1020227035524A priority patent/KR102712911B1/ko
Priority to AU2016425935A priority patent/AU2016425935B2/en
Priority to PCT/EP2016/076104 priority patent/WO2018065076A1/fr
Priority to US16/323,110 priority patent/US20190167700A1/en
Priority to CR20190112A priority patent/CR20190112A/es
Priority to PCT/EP2017/069908 priority patent/WO2018024912A1/fr
Priority to PE2019000262A priority patent/PE20190739A1/es
Priority to JP2017152175A priority patent/JP6557298B2/ja
Priority to BR112019002203-1A priority patent/BR112019002203A2/pt
Priority to MX2019001298A priority patent/MX2019001298A/es
Priority to PH1/2019/500172A priority patent/PH12019500172B1/en
Publication of WO2018065076A1 publication Critical patent/WO2018065076A1/fr
Priority to CONC2019/0000672A priority patent/CO2019000672A2/es
Priority to MX2022011436A priority patent/MX2022011436A/es
Priority to NI201900010A priority patent/NI201900010A/es
Priority to ECSENADI20198376A priority patent/ECSP19008376A/es
Anticipated expiration legal-status Critical
Priority to US16/573,611 priority patent/US20200046729A1/en
Priority to AU2022231672A priority patent/AU2022231672B2/en
Priority to US17/937,215 priority patent/US11896602B2/en
Priority to US19/009,804 priority patent/US20250360147A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Definitions

  • the present invention relates to a method of alleviating the symptoms of dysmenorrhea in a person, comprising administering to said person an effective amount of an estrogenic component. More particularly the estrogenic component is an estetrol component, as further defined herein, and the method enjoys a favourable side-effect profile compared to currently available methods.
  • Dysmenorrhea is a medical condition characterized by the presence of recurrent, crampy, lower abdominal pain that occurs during menses. Most women begin having dysmenorrhea during adolescence, usually within four to five years of the first menstrual period. Painful periods become less common as women age. For clinical purposes, dysmenorrhea is divided into two broad categories, primary and secondary dysmenorrhea. Primary dysmenorrhea refers to the presence of recurrent, crampy, lower abdominal pain that occurs during menses in the absence of demonstrable disease that could account for these symptoms.
  • Secondary dysmenorrhea has the same clinical features, but occurs in women with a disorder that could account for their symptoms, such as endometriosis, adenomyosis, or uterine fibroids.
  • Prostaglandins released from endometrial sloughing at the beginning of menses play a major role in inducing contractions (Ylikorkala O, Dawood MY.; Am J Obstet Gynecol 1978; 130:833).
  • the pain starts one to two days before or with the onset of menstrual bleeding and then gradually diminishes over 12 to 72 hours. It is recurrent, occurring in most, if not all, menstrual cycles.
  • the pain is usually crampy and intermittently intense, but may be a continuous dull ache. It is usually confined to the lower abdomen and suprapubic area. Although the pain is usually strongest in the midline, some women also have severe back and/or thigh pain.
  • the "dysmenorrhea symptoms grade” corresponds to the score obtained by applying the assessment presented in Table 1.
  • Table 1 Verbal multidimensional scoring system for assessment of dysmenorrhea
  • Grade 2 Daily activity is Moderately affected Few Required affected; analgesics required and
  • Nonsteroidal anti-inflammatory drugs are considered the first line of therapy (Proctor M, Farquhar C; Clin Evid 2003 ; : 1994 - Zhang WY, Li Wan Po A.; Br J Obstet Gynaecol 1998; 105:780 - French L.; Am Fam Physician 2005; 71 :285).
  • NSAIDs should be started at the onset of menses and continued for the first one to two days of the menstrual cycle or for the usual duration of crampy pain. Patients with severe symptoms should begin taking NSAIDs one to two days prior to the onset of menses.
  • COCs Combined Oral Contraceptive pills
  • COCs may be considered for first-line of therapy because they serve a dual purpose: prevention of both pregnancy and dysmenorrhea.
  • SHBG plasma levels are a reliable marker of the influence of an estrogen on the synthesis of these proteins by liver cells. This means that a correlation could exist between the level of SHBG induced by a specific COC and the risk of VTE associated with that COC (Odlind V, et al; Acta Obstet Gynecol Scand 2002; 81 :482).
  • the present invention relates to a method of alleviating the symptoms of dysmenorrhea in a person, comprising administering to said person an effective amount of an estrogenic component. More particularly the estrogenic component is an estetrol component, as further defined herein, and the method enjoys a favourable side-effect profile compared to currently available methods.
  • one or more of the number, the frequency and the severity of treatment-related side effects is reduced, compared to other dysmenorrhea treatments of similar efficacy.
  • the number, frequency and/or severity of VTE events is reduced, compared to other dysmenorrhea treatments of similar efficacy.
  • the number, frequency and/or severity of headaches is reduced, compared to other dysmenorrhea treatments of similar efficacy.
  • the number, frequency and/or severity of breast pain events is reduced, compared to other dysmenorrhea treatments of similar efficacy.
  • the method involves the administration of an effective amount of an estrogenic component and of a progestogenic component.
  • the estrogenic and the progestogenic components are included in a single dosage unit.
  • the dosage unit is a daily dosage unit.
  • the progestogenic component is drospirenone and that component is used at a daily dose of from 0.5 mg to 10 mg, preferably at a daily dose of from 1 mg to 4 mg.
  • the estrogenic component is used at a daily dose of from 1 mg to 40 mg, preferably at a daily dose of from 5 mg to 25 mg, even more preferably at a daily dose of from 10 mg to 20 mg.
  • the estrogenic component is estetrol monohydrate.
  • the estrogenic component is estetrol monohydrate at a daily dose of about 15 mg and the progestogenic component is drospirenone at a daily dose of about 3 mg.
  • the present method employs an estrogenic component which is a natural estrogen (i.e. found in nature) and a biogenic estrogen (i.e. occurring naturally in the human body).
  • biogenic estrogens are naturally present in the fetal and female body, a good tolerability and safety profile are observed, particularly if the serum levels resulting from the exogenous administration of such estrogens do not substantially exceed naturally occurring concentrations.
  • a direct consequence of this good tolerability is the favourable side-effect profile obtained with the method of the invention compared to other methods.
  • estrogenic component encompasses substances that are capable of triggering an estrogenic response in vivo, as well as precursors that are capable of liberating such an estrogenic component in vivo when used in accordance with the present invention.
  • estrogenic components In order for estrogenic components to trigger such a response they normally have to bind to an estrogen receptor, which receptors are found in various tissues within the mammalian body.
  • the estrogenic component of the present invention preferably is an estetrol component.
  • estetrol component encompasses substances selected from the group consisting of estetrol, esters of estetrol wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; and combinations thereof. Even more preferably, the estetrol component is estetrol (including estetrol hydrates). Most preferably, the estetrol component contained in the dosage unit is estetrol monohydrate.
  • progestogenic component is defined as a substance that is capable of triggering a progestogenic response in vivo or a precursor which is capable of liberating such a substance in vivo.
  • progestogenic components are capable of binding to a progestogen receptor.
  • an effective amount refers to an amount necessary to obtain a physiological effect. The physiological effect may be achieved by one dose or by repeated doses.
  • an effective amount refers to an amount which is effective in reducing, eliminating, treating or controlling the symptoms of dysmenorrhea.
  • controlling is intended to refer to all processes wherein there may be a slowing, interrupting, arresting, or stopping of the progression of dysmenorrhea, but does not necessarily indicate a total elimination of dysmenorrhea, and is intended to include prophylactic treatment and chronic use.
  • Example 5 the present method of alleviating the symptoms of dysmenorrhea has proved surprisingly efficient despite the low daily dosage employed.
  • the present inventors believe that the superiority of the present method is in part due to the surprising effect of the estetrol component which is capable of mitigating dysmenorrhea on its own, as illustrated in the clinical results presented in Example 1.
  • the estetrol component is capable of alleviating the symptoms of dysmenorrhea allows to decrease those symptoms when the estetrol component is administered alone according to the method of the invention.
  • the estetrol component is administered alone during the progestin-free interval of the method of treatment according to the invention, as further described below.
  • the present inventors believe that the superiority of the present method is also due to the mild stimulatory effect that the estetrol component has on the endometrium, especially by comparison with the stronger stimulatory effect of ethinyl estradiol, which is the estrogen used in a large number of COCs.
  • endometrial thickness was strongly diminished upon administration of the compositions of the invention.
  • the thin endometrium contains relatively small amounts of arachidonic acid, the substrate for most prostaglandin synthesis.
  • the compositions of the invention reduce both menstrual flow and uterine contractions at menses, thereby decreasing dysmenorrhea.
  • the method according to the invention was found to suppress ovulation in 100% of patients and suppression of ovulation is decreasing uterine prostaglandin levels.
  • estetrol component Another important benefit of the present estetrol component is derived from its relative insensitivity to interactions with other drugs (drug-drug interactions). It is well known that certain drugs may decrease the effectiveness of estrogens, such as ethinyl estradiol, and other drugs may enhance their activity, resulting in possible increased side- effects. Similarly estrogens may interfere with the metabolism of other drugs. In general, the effect of other drugs on estrogens is due to interference with the absorption, metabolism or excretion of these estrogens, whereas the effect of estrogens on other drugs is due to competition for metabolic pathways.
  • estrogen-drug interactions occurs with drugs that may induce hepatic microsomal enzymes which may decrease estrogen plasma levels below therapeutic level (for example, anticonvulsant agents; phenytoin, primidone, barbiturates, carbamazepine, ethosuximide, and methosuximide; antituberculous drugs such as rifampin; antifungal drugs such as griseofulvin).
  • drugs that may induce hepatic microsomal enzymes which may decrease estrogen plasma levels below therapeutic level
  • anticonvulsant agents for example, anticonvulsant agents; phenytoin, primidone, barbiturates, carbamazepine, ethosuximide, and methosuximide; antituberculous drugs such as rifampin; antifungal drugs such as griseofulvin.
  • the present estrogenic substances are not dependent on up- and downregulation of microsomal liver enzymes (e.g. P450's) and also are not sensitive to competition with other P450 substrates.
  • estetrol at a high concentration of 10 ⁇ / ⁇ does not inhibit (less than 10%) the major cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) unlike estradiol.
  • estradiol exerts a substantial inhibitory effect on CYP2C19 and CYP1A2 of 63 % and 19%, respectively.
  • ethinyl estradiol which is the estrogen used in a large number of COCs, exerts a substantial inhibitory effect on CYP2C19 and CYP3A4 of 82 % and 45%, respectively.
  • estetrol is associated with 3 mg drospirenone (DRSP) or 150 ⁇ g Levonorgestrel (LNG), the bleeding profile and the cycle control is improved in comparison to other combined oral contraceptives using a physiological estrogen, namely estradiol- valerate (E2V) or estradiol (E2).
  • estrogens ethinylestradiol (EE), E2, E2V, conjugated equine estrogens
  • E4 minimally increases triglycerides levels even at higher dosages.
  • VTEs venous thromboembolic events
  • the use of second generation COCs multiply by 2 the risk of VTE and the use of 3rd and 4th COCs multiply the risk by 4.
  • the absolute risk of VTE associated with the use of a specific combined contraceptive can only be assessed during very large epidemiological trials.
  • several surrogate markers of the VTE risk can be measured in smaller clinical settings to estimate the risk.
  • Example 4 From the clinical results obtained with combinations of E4 and DRSP or LNG, the changes in the surrogate markers of VTE were minimal in comparison to the changes observed with Yaz® (a combination of 20 ⁇ g EE and 3 mg DRSP).
  • DRSP is a fourth generation progestin associated with the highest risk of VTE when it is combined with the synthetic estrogen EE. Accordingly, the changes in the surrogate markers of VTE seen with a combination of EE and DRSP are substantial. In comparison, the changes observed with the E4 combinations are minimal even when DRSP is associated to the estrogen.
  • the SHBG plasma level changes observed when E4 was associated with 3 mg DRSP were considerably lower (mean percentage change of 7.9% for the 5 mg E4/3 mg DRSP group and of 44.5% for the 10 mg E4/3 mg DRSP group at treatment cycle 3) than the SHBG increases observed with a combination of 20 ⁇ g EE and 3 mg DRSP (mean percentage change of 306.3 % for Yaz® at treatment cycle 3).
  • the same positive pattern of change was observed with the 14 additional surrogate markers of VTE measured in this trial.
  • the present methods usually employ uninterrupted oral administration of the estrogenic component and the progestogenic component during a period of at least 10 days, preferably of at least 20 days.
  • the term "uninterrupted" as used in here means that the components are administered at relatively regular intervals, with no (therapeutically) significant interruptions. Naturally, minor interruptions may occur that do not affect the overall effectiveness of the present method, and indeed such aberrations are encompassed by the present invention.
  • the administration regimen is deemed to be continuous if the longest interval between 2 subsequent administrations is not more than 3.5 times as long as the average interval. Even more preferably said longest interval is not more than 2.5 times, most preferably not more than 1.5 times as long as the average interval.
  • the estrogenic and progestogenic components may be administered in separate dosage units. However, it is also possible and indeed very convenient to combine these two components into a single dosage unit.
  • the combination of the progestogenic and estrogenic component is suitably administered uninterruptedly during a period of at least 10 days.
  • the invention may suitably be reduced to practice in the form of a variety of administration methods that are known to the person skilled in the art. Amongst these methods are the so called “combined” methods.
  • the combined methods make use of monophasic preparations, which contain dosage units with a constant amount of an estrogen and a progestogen, or bi- or triphasic preparations which have varying levels of estrogen and progestogen; in most cases consisting of relatively constant levels of estrogen with a step-wise increase in progestogen throughout the cycle.
  • the combined methods have in common that they are based on a regimen which involves an administration- free interval of about 7 days whereby withdrawal bleeding, simulating the natural menses, occurs. Thus 21 day intervals of hormone administration alternate with 7 days during which no hormones are administered.
  • an administration- free interval of about 4 days is used.
  • a 24 day interval of hormone administration alternates with 4 days during which no hormones are administered.
  • a 24 day interval of hormone administration during which an estrogenic component and a progestogenic component are administered alternates with 4 days during which only an estrogenic component is administered (from day 25 to day 28).
  • the so called “sequential" method has been proposed.
  • Typical of the sequential method is that it comprises two consecutive phases, i.e. one phase during which estrogen and no progestogen is administered and another phase during which a combination of estrogen and progestogen is administered.
  • the first sequential methods like the aforementioned combined methods, made use of an administration free interval of about 7 days. More recently, sequential methods have been proposed which do not include an administration- free (or placebo) period, meaning that estrogen is administered throughout the full cycle and that progestogen is co-administered during only part of that cycle.
  • WO 95/17895 (Ehrlich et al.) describes such an uninterrupted sequential method.
  • Yet another example of a method which is encompassed by the present invention is the so called "continuous combined" method, which is a particular version of the combined method that uses uninterrupted combined administration of a progestogenic and an estrogenic component during a prolonged period of time, e.g. more than 50 days.
  • continuous combined a method which is encompassed by the present invention
  • no regular menses occur in the continuous combined method as the continuous administration of progestogen in the indicated amounts induces amenorrhoea.
  • the present method comprises the uninterrupted oral administration of the combination of the estrogenic component and the progestogenic component during a period of at least 28, preferably at least 60 days.
  • the method of the invention comprises an interval of at least 2 days, preferably from 3-9 days, most preferably from 5-8 days, during which no progestogenic component and no estrogenic component is administered and wherein the resulting decrease in serum concentration of the progestogenic component and the estrogenic component induces menses.
  • Yet another embodiment of the invention which concerns a sequential method without a significant pause, is characterised in that it comprises the uninterrupted oral administration of the estrogenic component during a period of at least 28 days, preferably at least 60 days, and in that, following the combined administration of the estrogenic component and the progestogenic component, the estrogenic component and no progestogenic component are administered during 3-18 consecutive days, preferably during 5-16 consecutive days and the resulting decrease in serum concentration of the progestogenic component should normally be sufficient to induce menses.
  • the composition for use in a method of alleviating the symptoms of dysmenorrhea is capable of reducing the number, frequency and/or severity of adverse side effects including VTE, headache, breast pain, and the like, preferably including VTE, headache, and breast pain, more preferably including VTE and headache, and most preferably including VTE.
  • the composition according to the present invention is particularly useful for effective treatment of the symptoms of dysmenorrhea while reducing the side effect of VTE at a significantly low frequency and severity.
  • the method does not cause haemostatic change that exceeds the boundaries of the normal range.
  • haemostatic change is defined as the variation, upon administration of the compositions according to the invention, of the plasma level of one or more markers selected from: Sex Hormone Binding Globulin (SHBG), free tissue factor pathway inhibitor (free TFPI), free and total protein-S, protein-S activity, Corticosteroid Binding Globulin (CBG), Ceruloplasmin, antithrombin III, activated protein C (APC) resistance (e.g.
  • SHBG Sex Hormone Binding Globulin
  • free TFPI free tissue factor pathway inhibitor
  • CBG Corticosteroid Binding Globulin
  • Ceruloplasmin Ceruloplasmin
  • antithrombin III activated protein C (APC) resistance
  • APTT-based APCr or ETP-based APCr Protein-C activity, D-dimer, Prothrombin, Prothrombin fragment 1+2, Factor VII, Factor VIII, von Willebrand factor, Factor II, PAI-1, tissue- type plasminogen (t-PA), plasminogen, E-selectin, and fibrinogen.
  • the "normal range” when referring to levels of haemostatic markers, refers to the prediction interval that 95% of the population fall into.
  • the method does not cause haemostatic change exceeding the boundaries of the normal range after one cycle of treatment, preferably the method does not cause haemostatic change exceeding the boundaries of the normal range after two cycles of treatment, even more preferably the method does not cause haemostatic change exceeding the boundaries of the normal range after three cycles of treatment.
  • the method does not cause a change in the level of protein-S which exceeds the boundaries of the normal range.
  • the method does not cause a change in the level of free TFPI which exceeds the boundaries of the normal range.
  • the estrogenic component of the present invention preferably is an estetrol component, which encompasses substances selected from the group consisting of estetrol, esters of estetrol wherein the hydrogen atom of at least one of the hydroxyl groups has been substituted by an acyl radical of a hydrocarbon carboxylic, sulfonic acid or sulfamic acid of 1-25 carbon atoms; and combinations thereof. Even more preferably, the estetrol component is estetrol (including estetrol hydrates). Most preferably, the estetrol component contained in the dosage unit is estetrol monohydrate.
  • the estetrol component of the invention may be used at a daily dose of from
  • the estetrol component of the invention is used at a daily dose of from 1 mg to 40 mg. Even more preferably, the estetrol component of the invention is used at a daily dose of from 5 mg to 25 mg. Still more preferably, the estetrol component of the invention is used at a daily dose of from 10 mg to 20 mg.
  • estetrol component of the invention is used at a daily dose of about 15 mg.
  • dosages may be variable throughout the cycle (bi-phasic, tri-phasic or quadriphasic administration).
  • progestogenic components which may suitably be used in accordance with the present invention include: levonorgestrel, norgestimate, norethisterone, dydrogesterone, drospirenone, 3-beta-hydroxydesogestrel, 3-ketodesogestrel, 17- deacetylnorgestimate, 19-norprogesterone, acetoxypregnenolone, allylestrenol, amgestone, chlormadinone, cyproterone, demegestone, desogestrel, dienogest, dihydrogesterone, dimethisterone, ethisterone, ethynodiol diacetate, fluorogestone acetate, gastrinone, gestodene, gestrinone, hydroxymethylprogesterone, hydroxyprogesterone
  • the progestogenic component used in the present method is selected from the group consisting of progesterone, desogestrel, gestodene, dienogest, levonorgestrel, norgestimate, norethisterone, drospirenone, trimegestone, dydrogesterone, precursors of these progestogens and mixtures thereof.
  • the progestogenic component of the invention is drospirenone
  • it is preferably used at a daily dose of from 0.5 mg to 10 mg, even more preferably of from 1 mg to 4 mg.
  • the progestogenic component of the invention is drospirenone and it is used at a daily dose of about 3 mg.
  • the daily dose is adjusted such as to give the same pharmacological effect as a dose of 0.5 mg to 10 mg of drospirenone, preferably to give the same pharmacological effect as a dose of 1 mg to 4 mg of drospirenone.
  • the composition combines estetrol at a daily dose of from 5 mg to 25 mg with drospirenone at a daily dose of 0.5 mg to 10 mg. In a more preferred embodiment of the invention, the composition combines estetrol at a daily dose of from 10 mg to 20 mg with drospirenone at a daily dose of 1 mg to 4 mg. In a yet more preferred embodiment of the invention, the composition combines estetrol at a daily dose of about 15 mg with drospirenone at a daily dose of about 3 mg.
  • dysmenorrhea was reported by 11 subjects (21.2%), and frequent dysmenorrhea was reported by 19 subjects (36.5%>).
  • the distribution of dysmenorrhea is shown in Table 2 below. Overall, dysmenorrhea was reported by 25% to 53.3% of the subjects included in this trial.
  • dysmenorrhea TE-AEs leading to discontinuation occurred once in each of the 20 mg E4 groups (1.3%) but did not occur in any of the 15 mg E4 groups (0%).
  • the method of the invention permits to minimize the SHBG level changes from baseline both at Cycle 4 and at Cycle 6, compared to a commercially available COC which also uses a natural estrogen.
  • Table 7 Mean (SD) percentage change from baseline to end of treatment Cycle 3 for haemostasis parameters and carrier proteins, in women using a combination of E4/DRSP or EE/DRSP
  • Prothrombin fragment 1+2 -24.1 (15.97) -1.3 (28.63) 63.4(50.21)
  • E4 estetrol; EE, ethinylestradiol; DRSP, drospirenone; APC, activated protein C; TFPI, tissue factor pathway inhibitor; tPA, tissue type plasminogen; CBG, corticosteroid binding globulin; SHBG, sex hormone binding globulin.
  • SHBG is considered as the most relevant biomarker for estrogenic impact of a COC on liver metabolism (Odlind V. et al; Acta Obstet Gynecol Scand 2002; 81 :482).
  • CBG and ceruloplasmin are essentially synthesized under the influence of estrogens and are much less sensitive to the androgenic action of progestins.
  • increasing the dose of estrogen resulted in a slight increase from baseline for CBG and ceruloplasmin.
  • by far the largest change from baseline was observed in the EE/DRSP group compared to the E4 treatment groups.
  • a multicenter, open label, placebo-controlled, randomised study to evaluate the benefits of the method of the invention on alleviating complaints of dysmenorrhea was conducted.
  • the study population consisted in healthy female subjects, between 12 and 35 years old, inclusive (at the time of screening), with primary dysmenorrhea (onset ⁇ 3 years post menarche).
  • the product according to the method of the invention was a combination tablet with estetrol (15 mg) and drospirenone (3 mg) administered orally once daily in continuous or 24/4-day regimen (i.e. 24 days of active tablets followed by 4 days of placebo tablets). Other doses of estetrol were included in supplementary arms, in addition to the placebo arm.
  • the efficacy of the method of the invention was demonstrated by following the change between baseline evaluation period and treatment evaluation period, primarily in the number of days with dysmenorrhea pain.
  • Dysmenorrhea pain was defined as pelvic pain during the menstrual/withdrawal bleeding episode and the 2 days before this episode.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode de prise en charge de la dysménorrhée, consistant à administrer un composant œstrogénique qui est de préférence sélectionné dans le groupe constitué par l'estétrol et des composés de type estétrol. Étonnamment, les composés de type estétrol se sont révélés aptes à atténuer la dysménorrhée, lorsqu'ils sont utilisés seuls ou combinés à des composés progestatifs, dans une mesure qui dépasse l'effet obtenu avec d'autres compositions, et avec un profil d'effets secondaires avantageux par rapport aux méthodes actuellement disponibles.
PCT/EP2016/076104 2016-08-05 2016-10-28 Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles Ceased WO2018065076A1 (fr)

Priority Applications (24)

Application Number Priority Date Filing Date Title
CA3178291A CA3178291A1 (fr) 2016-08-05 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
MYPI2019002318A MY205032A (en) 2016-10-28 2016-10-28 Method for the management of dysmenorrhea and menstrual pain
JP2017529086A JP2018533542A (ja) 2016-10-28 2016-10-28 月経困難症および月経痛の管理のための方法
CA3041016A CA3041016C (fr) 2016-10-28 2016-10-28 Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
KR1020197015235A KR102780201B1 (ko) 2016-10-28 2016-10-28 월경통 및 생리통의 관리방법
KR1020227035524A KR102712911B1 (ko) 2016-08-05 2016-10-28 월경통 및 생리통의 관리방법
AU2016425935A AU2016425935B2 (en) 2016-10-28 2016-10-28 Method for the management of dysmenorrhea and menstrual pain
PCT/EP2016/076104 WO2018065076A1 (fr) 2016-10-28 2016-10-28 Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles
JP2017152175A JP6557298B2 (ja) 2016-08-05 2017-08-07 副作用（ｖｔｅリスク、頭痛）を軽減し、月経困難症および月経痛の症状を軽減する方法
PH1/2019/500172A PH12019500172B1 (en) 2016-08-05 2017-08-07 Method for the management of dysmenorrhea and menstrual pain
CR20190112A CR20190112A (es) 2016-08-05 2017-08-07 Procedimiento de manejo de dismenorrea y dolor menstrual
PCT/EP2017/069908 WO2018024912A1 (fr) 2016-08-05 2017-08-07 Méthode de gestion de la dysménorrhée et de la douleur menstruelle.
PE2019000262A PE20190739A1 (es) 2016-08-05 2017-08-07 Procedimiento de tratamiento de dismenorrea y dolor menstrual
US16/323,110 US20190167700A1 (en) 2016-08-05 2017-08-07 Method for the management of dysmenorrhea and menstrual pain
BR112019002203-1A BR112019002203A2 (pt) 2016-08-05 2017-08-07 método para o controle de dismenorreia e dor menstrual
MX2019001298A MX2019001298A (es) 2016-08-05 2017-08-07 Metodo de manejo de dismenorrea y dolor menstrual.
CONC2019/0000672A CO2019000672A2 (es) 2016-08-05 2019-01-24 Procedimiento de tratamiento de dismenorrea y dolor menstrual
MX2022011436A MX2022011436A (es) 2016-08-05 2019-01-30 Metodo de manejo de dismenorrea y dolor menstrual.
NI201900010A NI201900010A (es) 2016-08-05 2019-02-01 Procedimiento de manejo de dismenorrea y dolor menstrual
ECSENADI20198376A ECSP19008376A (es) 2016-08-05 2019-02-05 Procedimiento de manejo de dismenorrea y dolor menstrual
US16/573,611 US20200046729A1 (en) 2016-08-05 2019-09-17 Methods using combined oral contraceptive compositions with reduced cardiovascular effects
AU2022231672A AU2022231672B2 (en) 2016-08-05 2022-09-13 Method for the management of dysmenorrhea and menstrual pain
US17/937,215 US11896602B2 (en) 2016-08-05 2022-09-30 Method for preventing pregnancy
US19/009,804 US20250360147A1 (en) 2016-08-05 2025-01-03 Methods using combined oral contraceptive compositions with reduced cardiovascular effects

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2016/076104 WO2018065076A1 (fr) 2016-10-28 2016-10-28 Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles

Publications (1)

Publication Number Publication Date
WO2018065076A1 true WO2018065076A1 (fr) 2018-04-12

Family

ID=57209484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/076104 Ceased WO2018065076A1 (fr) 2016-08-05 2016-10-28 Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles

Country Status (6)

Country Link
JP (1) JP2018533542A (fr)
KR (1) KR102780201B1 (fr)
AU (1) AU2016425935B2 (fr)
CA (1) CA3041016C (fr)
MY (1) MY205032A (fr)
WO (1) WO2018065076A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019154899A1 (fr) 2018-02-07 2019-08-15 Estetra Sprl Composition contraceptive présentant des effets cardiovasculaires réduits
US10660903B2 (en) 2015-06-18 2020-05-26 Estetra Sprl Orodispersible dosage unit containing an estetrol component
US10844088B2 (en) 2011-07-19 2020-11-24 Estetra Sprl Process for the preparation of estetrol
CN112020360A (zh) * 2018-04-19 2020-12-01 依思特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
WO2021044302A1 (fr) 2019-09-03 2021-03-11 Richter Gedeon Nyrt. Procédé industriel pour la préparation d'estétrol de pureté élevée
US11147771B2 (en) 2015-06-18 2021-10-19 Estetra Sprl Orodispersible dosage unit containing an estetrol component
US11484539B2 (en) 2018-04-19 2022-11-01 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
CN116669732A (zh) * 2021-02-02 2023-08-29 广州沪同有梧生物科技有限公司 Pqq及其衍生物的新应用
US11896602B2 (en) 2016-08-05 2024-02-13 Estetra Srl Method for preventing pregnancy
WO2025181710A1 (fr) 2024-02-28 2025-09-04 Richter Gedeon Nyrt. Procédé de cristallisation de monohydrate d'estétrol
US12458649B2 (en) 2020-04-16 2025-11-04 Estetra Srl Contraceptive compositions with reduced adverse effects

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000003964A1 (it) * 2020-02-26 2021-08-26 Umberto Cornelli Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017895A1 (fr) 1993-12-24 1995-07-06 Marika Ehrlich Agents et procede pour la contraception hormonale et/ou pour le traitement de l'acne
WO2012055840A1 (fr) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102712911B1 (ko) * 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017895A1 (fr) 1993-12-24 1995-07-06 Marika Ehrlich Agents et procede pour la contraception hormonale et/ou pour le traitement de l'acne
WO2012055840A1 (fr) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
AL-JEFOUT MOAMAR ET AL: "Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 [mu]g for the Management of Primary Dysmenorrhea in Young Adult Women", JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 29, no. 2, 3 September 2015 (2015-09-03), pages 143 - 147, XP029421056, ISSN: 1083-3188, DOI: 10.1016/J.JPAG.2015.08.009 *
ANDERSCH B; MILSOM I., AM J OBSTET GYNECOL, vol. 144, 1982, pages 655
CALLEJO J ET AL., CONTRACEPTION, vol. 68, 2003, pages 183
COELINGH BENNINK H J T ET AL: "Estetrol review: profile and potential clinical applications", CLIMACTERIC, vol. 11, no. Suppl.1, 2008, pages 47 - 58, XP009194877 *
DAVIS AR ET AL., OBSTET GYNECOL, vol. 106, 2005, pages 97
ENDRIKAT J ET AL., CONTRACEPTION, vol. 52, 1995, pages 229
FRENCH L., AM FAM PHYSICIAN, vol. 71, 2005, pages 285
HENDRIX SL; ALEXANDER NJ., CONTRACEPTION, vol. 66, 2002, pages 393
ODLIND V ET AL., ACTA OBSTET GYNECOL SCAND, vol. 81, 2002, pages 482
ODLIND V. ET AL., ACTA OBSTET GYNECOL SCAND, vol. 81, 2002, pages 482
PROCTOR M; FARQUHAR C, CLIN EVID, 2003, pages 1994
SUNDELL G. ET AL., BR J OBSTET GYNAECOL, vol. 97, 1990, pages 588
WINKLER UH ET AL., CONTRACEPTION, vol. 69, 2004, pages 469
WONG CL ET AL., COCHRANE DATABASE SVST REV, 2009
YLIKORKALA O; DAWOOD MY., AM J OBSTET GYNECOL, vol. 130, 1978, pages 833
ZEEV HAREL: "Dysmenorrhea in adolescents and young adults: an update on pharmacological treatments and management strategies", EXPERT OPINION ON PHARMACOTHERAPY, vol. 13, no. 15, 18 September 2012 (2012-09-18), LONDON, UK, pages 2157 - 2170, XP055389783, ISSN: 1465-6566, DOI: 10.1517/14656566.2012.725045 *
ZHANG WY; LI WAN PO A., BR J OBSTET GYNAECOL, vol. 105, 1998, pages 780

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10844088B2 (en) 2011-07-19 2020-11-24 Estetra Sprl Process for the preparation of estetrol
US11964055B2 (en) 2015-06-18 2024-04-23 Estetra Srl Orodispersible dosage unit containing an estetrol component
US10660903B2 (en) 2015-06-18 2020-05-26 Estetra Sprl Orodispersible dosage unit containing an estetrol component
US11957694B2 (en) 2015-06-18 2024-04-16 Estetra Srl Orodispersible dosage unit containing an estetrol component
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
US11147771B2 (en) 2015-06-18 2021-10-19 Estetra Sprl Orodispersible dosage unit containing an estetrol component
US11896602B2 (en) 2016-08-05 2024-02-13 Estetra Srl Method for preventing pregnancy
WO2019154899A1 (fr) 2018-02-07 2019-08-15 Estetra Sprl Composition contraceptive présentant des effets cardiovasculaires réduits
CN112020360A (zh) * 2018-04-19 2020-12-01 依思特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
US12458651B2 (en) 2018-04-19 2025-11-04 Estetra Srl Compounds and their uses for alleviating menopause-associated symptoms
US12390478B2 (en) 2018-04-19 2025-08-19 Estetra Srl Compounds and their uses for alleviating menopause-associated symptoms
US11666585B2 (en) 2018-04-19 2023-06-06 Estetra Srl Compounds and their uses for alleviating menopause-associated symptoms
US11484539B2 (en) 2018-04-19 2022-11-01 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
US11452733B2 (en) 2018-04-19 2022-09-27 Estetra Sprl Compounds and their uses for alleviating menopause-associated symptoms
WO2021044302A1 (fr) 2019-09-03 2021-03-11 Richter Gedeon Nyrt. Procédé industriel pour la préparation d'estétrol de pureté élevée
US11633406B2 (en) 2019-09-03 2023-04-25 Richter Gedeon Nyrt. Industrial process for the preparation of high purity estetrol
EP3877395B1 (fr) 2019-09-03 2022-12-07 Richter Gedeon Nyrt. Procédé industriel pour la préparation d'estétrol de pureté élevée
US12458649B2 (en) 2020-04-16 2025-11-04 Estetra Srl Contraceptive compositions with reduced adverse effects
CN116669732A (zh) * 2021-02-02 2023-08-29 广州沪同有梧生物科技有限公司 Pqq及其衍生物的新应用
EP4269410A4 (fr) * 2021-02-02 2024-07-17 Guangzhou Hutongyouwu Biotechnology Co., Ltd Nouvelle utilisation de pqq et de son dérivé
WO2025181710A1 (fr) 2024-02-28 2025-09-04 Richter Gedeon Nyrt. Procédé de cristallisation de monohydrate d'estétrol

Also Published As

Publication number Publication date
JP2018533542A (ja) 2018-11-15
MY205032A (en) 2024-09-28
AU2016425935A1 (en) 2019-05-16
KR102780201B1 (ko) 2025-03-12
AU2016425935B2 (en) 2023-01-19
KR20190076014A (ko) 2019-07-01
CA3041016C (fr) 2023-09-05
CA3041016A1 (fr) 2018-04-12

Similar Documents

Publication Publication Date Title
AU2022231672B2 (en) Method for the management of dysmenorrhea and menstrual pain
AU2016425935B2 (en) Method for the management of dysmenorrhea and menstrual pain
US5468736A (en) Hormone replacement therapy
US20200046729A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
JP2013139464A (ja) 避妊用の組成
IL187471A (en) Quadraphasic continuous graduated estrogen contraceptive
EP1796725B1 (fr) Traitement ou prevention des hemorragies occasionnelles chez les femmes sous progestogenotherapie
CN111683664A (zh) 具有降低的心血管作用的避孕组合物
PT1740163E (pt) Preparação contraceptiva multifásica à base de um estrogénio natural
US20250360147A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
Von Schoultz Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment
JPH08508502A (ja) 骨粗しょう症の治療方法および治療用組成物
JP2008527018A (ja) 避妊用医薬製剤
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein
HK1112200A (en) Contraceptive pharmaceutical preparation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2017529086

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16788120

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3041016

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016425935

Country of ref document: AU

Date of ref document: 20161028

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20197015235

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 16788120

Country of ref document: EP

Kind code of ref document: A1